Ann: Immutep expands Part A of TACTI-002 due to positive data, page-8

The decision by the Data Monitoring Committee (DMC) to open cohort 2 follows the review of preliminarysafety and efficacy data and their recommendation is based on predefined safety and efficacy thresholds.

After 6 months....

For seven out of 17 (41.2 %) a partial response (PR) according to RECIST 1.1 was observed as the best overallresponse (BOR) as of the data cut-off (September 6, 2019) in this interim analysis.

An additional six patientshad a stabilization of disease (SD) as best overall response at this point leading to a disease control rate of76.5 % in this highly aggressive tumour entity. Twelve patients are currently continuing treatment.

Patientswere allowed to participate regardless of their PD-L1 status which is a well-known predictive marker forresponse to pembrolizumab in NSCLC.....